Study | Cost outcomes | US$ PPP in 2011 |
---|---|---|
Bramley et al15 | Annual costs per patient compared in degrees of vision impairment from no vision loss to onset of moderate or severe vision impairment or blindness | |
No vision loss US$8157 | 8695 | |
Moderate visual impairment US$13 162 | 14 029 | |
Severe visual impairment US$15 312 | 16 321 | |
Blindness US$18 670 | 19 900 | |
Frick et al22 | Total expenditures on healthcare in blind and visually impaired persons ≥40 years | |
Blindness individual excess medical expenditures US$2157 | 2621 | |
Total excess medical expenditures US$2454 million | 2982 million | |
Visual impairment individual excess medical expenditures US$1037 | 1260 | |
Total excess medical expenditure US$2661 million | 3233 million | |
Total annual monetary impact for VI and blindness (primarily owing to home care) US$5100 million | 6197 million | |
Frick et al21 | Cohort with legally blind patients matched to an equal sample cohort with non-blind patients (annual costs per patient in the first year) | |
Blind persons mean costs US$20 677 | 24 180 | |
Median costs US$6854 | 8015 | |
Non-blind mean costs US$13 321 | 15 578 | |
Median costs US$371 | 434 | |
Javitt et al23 | Patients with normal vision compared to moderate or severe visual impairment or blindness regarding eye-related and non-eye-related care | |
Mean annual costs for eye-related care | ||
Normal vision US$370 | 445 | |
Moderate visual impairment US$345 | 415 | |
Severe visual impairment US$407 | 490 | |
Blindness US$237 | 285 | |
Mean annual values for non-eye related costs | ||
Normal vision US$7928 | 9537 | |
Moderate visual impairment US$2193 | 2638 | |
Severe visual impairment US$3301 | 3971 | |
Blindness US$4443 | 5345 | |
Kymes et al25 | Lifetime costs of POAG (primary open-angle glaucoma) to non-POAG patients | |
Incidence costs US$41 039 | 46 456 | |
Prevalence costs US$19 268 | 21 811 | |
Drug costs US$7098 | 8035 | |
Incremental incidence costs US$27 326 | 30 933 | |
Incremental prevalence costs US$5555 | 6288 | |
Incremental drug costs US$4179 | 4731 | |
Morse et al28 | Extension of average length of stay in hospitals due to visual impairment | |
5.2 days longer stay | ||
Cruess et al19 | Financial burden of vision loss to Canadian healthcare system | |
Hospital $C1497.7 million | 1934.72 million | |
Physicians $C866.5 million | 1119.34 million | |
Vision care $C3483.7 million | 4500.24 million | |
Chou et al17 | The out-of-pocket expenses for medicines and products per person annually | |
$A206 | 456 | |
Wong et al35 | Annual costs for medicine and products per patient | |
Visual acuity (VA) ≥6/18 with restr. field $A285 | 632 | |
<6/18—6/60=$A233 | 516 | |
< 6/60=$A147 | 326 | |
Clarke et al18 | Short-term and long-term annual hospital and non-hospital costs due to major diabetes-related complications | |
Blindness in one eye (in 20% of patients) £ 4370 | 4086 | |
Mean hospital in-patient costs £872 | 815 | |
Roberts et al31 | Total economic costs of visual impairment | |
General medical expenditure US$8.102 billion | 8636 million | |
In-patient US$1808 billion | 1927 million | |
Outpatient US$6.294 billion | 6709 million | |
Drugs US$1.395 billion | 1487 million |
POAG,primary open-angle glaucoma; VA,visual acuity.